Skip to main content

Drug Interactions between Hadlima and rilonacept

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

adalimumab rilonacept

Applies to: Hadlima (adalimumab) and rilonacept

GENERALLY AVOID: The use of an interleukin-1 (IL-1) blocker in combination with a tumor necrosis factor (TNF) blocker may increase the risk of neutropenia and serious infections, possibly due to additive immunosuppressive effects. In a clinical study, neutropenia occurred in 3% and serious infections in 7% of patients receiving the IL-1 blocker anakinra in combination with a TNF blocker (n=58). No added benefit has been observed with the combination relative to either agent alone.

MANAGEMENT: Concomitant use of an IL-1 blocker and a TNF blocker is not recommended.

References (8)
  1. (2001) "Product Information. Kineret (anakinra)." Amgen
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Pharmaceutical Society of Australia (2006) APPGuide online. Australian prescription products guide online. http://www.appco.com.au/appguide/default.asp
  4. Cerner Multum, Inc. "Australian Product Information."
  5. (2008) "Product Information. Cimzia (certolizumab)." UCB Pharma Inc
  6. (2008) "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc
  7. (2009) "Product Information. Simponi (golimumab)." Centocor Inc
  8. (2009) "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer